Sangamo Therapeutics Inc (SGMO.OQ)
12 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|54||2016||President, Chief Executive Officer, Director|
|45||2017||Chief Financial Officer, Senior Vice President|
|44||2016||Senior Vice President and Chief Medical Officer|
|36||2016||Senior Vice President and Chief Business Officer|
|60||2004||Vice President - Therapeutic Development, Chief Medical Officer|
- BRIEF-Sangamo Says European Medicines Agency Recommends Orphan Medicinal Product Designation For Investigational Genome Editing Treatments
- $1 million price tag in spotlight as gene therapy becomes reality
- BRIEF-Sangamo says patient received therapy intended to precisely edit DNA of cells directly inside body
- BRIEF-Sangamo Therapeutics posts Q3 loss per share $0.15
- BRIEF-Sangamo and Bioverativ announce FDA acceptance of IND application for ST-400